Cachexia index as a prognostic indicator in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab: multicenter analysis
International Journal of Clinical Oncology · 2026
DOI: 10.1007/s10147-026-03041-y ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Clinical Oncology, 2026. Verfasst von Shimpei Yamashita und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-0012, Japan. keito608@wakayama-med.ac.jp. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Cachexia, Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The association between cachexia index (CXI) and prognosis in patients with metastatic renal cell carcinoma (RCC) is unclear. We investigated the prognostic impact of pretreatment CXI in patients with metastatic RCC that were receiving nivolumab plus ipilimumab (NIVO + IPI) as a first-line therapy. METHODS: This multicenter retrospective cohort study included 141 patients who were treated with NIVO + IPI as a first-line treatment for metastatic RCC and whose pretreatment CXI was available. They were dichotomized using the median CXI, and we compared progression-free survival (PFS) and overall survival (OS) between the groups. Cox proportional regression analyses sought to identify the predictors of PFS and OS. RESULTS: The median CXI value was 47.1. The rates of no prior resection of the primary site and IMDC poor risk in the low CXI group were significantly higher than those in the high CXI group. The low CXI group had significantly lower PFS and OS than the high CXI group (median: 6 months vs. 14 months, P < 0.01 and median: 18 months vs. 52 months, P < 0.01, respectively). In multivariable analyses, no resection of the primary site was the only significant predictor of poor PFS (P = 0.03). Meanwhile, low CXI was a significant predictor of poor OS (P = 0.03) in addition to no prior resection of primary site and histologic subtype other than clear cell RCC (P < 0.01 and P < 0.01, respectively). CONCLUSIONS: Pretreatment CXI could become a useful prognostic marker in patients with metastatic RCC receiving NIVO + IPI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-0012, Japan. keito608@wakayama-med.ac.jp.
- Department of Urology, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-0012, Japan.
- Department of Nephro-Urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.
- Department of Urology, Graduate School of Medicine, Kobe University, Kobe, Japan.
- Department of Urology, Faculty of Medicine, Kindai University, Osakasayama, Japan.
- Department of Urology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
Zitieren
APA
Yamashita, S., Deguchi, R., Hamamoto, S., Bando, Y., Toyoda, S., Tomida, R., Miyake, M., Ito, N., Yamaguchi, N., Furukawa, J., Fujita, K., Hara, I., & Kohjimoto, Y. (2026). Cachexia index as a prognostic indicator in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab: multicenter analysis. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-026-03041-y
Vancouver
Yamashita S, Deguchi R, Hamamoto S, Bando Y, Toyoda S, Tomida R, et al. Cachexia index as a prognostic indicator in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab: multicenter analysis. International Journal of Clinical Oncology. 2026. doi:10.1007/s10147-026-03041-y
BibTeX
@article{Yamashita2026,
author = {Yamashita, Shimpei and Deguchi, Ryusuke and Hamamoto, Shuzo and Bando, Yukari and Toyoda, Shingo and Tomida, Ryotaro and Miyake, Makito and Ito, Noriyuki and Yamaguchi, Noriya and Furukawa, Junya and Fujita, Kazutoshi and Hara, Isao and Kohjimoto, Yasuo},
title = {Cachexia index as a prognostic indicator in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab: multicenter analysis},
journal = {International Journal of Clinical Oncology},
year = {2026},
doi = {10.1007/s10147-026-03041-y}
}
EUVIMED